The evidence for the involvement of cholinergic muscarinic receptors in mania and depression is reviewed. Small pilot trials with cholinesterase inhibitors and muscarinic agonists suggest that stimulation of muscarinic receptors may produce an antimanic effect, possibly by activation of muscarinic M 4 receptors. It is concluded that it is not likely that currently used mood stabilizers, such as lithium, valproic acid and carbamazepine, work directly through muscarinic receptor mechanisms. Furthermore, the evidence indicates that antipsychotic agents used for mania are working through the common mechanism of antagonism of dopamine D 2 receptors, and interactions with muscarinic receptors do not play a key role. Finally, it is hypothesized that olanzapine has robust antimanic activity, due to blockade of dopamine D 2 receptors and antagonism of other monoaminergic receptors. Olanzapine may normalize mood due to antidepressant-like activities, such as 5-HT 2A receptor antagonism and increasing cortical norepinephrine and dopamine.
Introduction
Bipolar disorder (manic-depressive illness) is a chronic illness manifested by periodic extreme changes in affective state and a lifetime prevalence of 1.2%. 1 Dysregulation of synaptic signaling in limbic and associated cortical and subcortical areas has been hypothesized to be central in the cyclical changes in behavioral states from mania to depression. 2 It has been hypothesized that dysfunction of many neurotransmitter systems, including the cholinergic muscarinic system, is involved in bipolar disorder. We review the evidence for dysfunction of the cholinergic muscarinic system in bipolar disorder, effects of currently used mood stabilizers on muscarinic neurotransmission and potential muscarinic receptor-mediated therapeutic effects of typical antipsychotics and the psychotropic agent olanzapine in bipolar disorder. Finally, we describe a potential new approach to the treatment of bipolar disorder using a muscarinic M 4 agonist. The effect of cholinergic nicotinic receptors on mood has been described recently 3 and will not be included in this review.
Organization of the cholinergic neuronal system
The cholinergic system with acetylcholine as its neurotransmitter has been subdivided into nicotinic and muscarinic receptor subtypes based on the selective affinity of nicotine and muscarine, respectively. Nicotinic receptors are ligand gated ion channels, whereas muscarinic receptors belong to the super family of plasma membrane-bound G protein coupled receptors. Currently, five subtypes of muscarinic receptors have been cloned, sequenced and extensively studied. It is thought that the muscarinic receptors are folded through seven hydrophobic domains spanning the plasma membrane. 4 Activation of the muscarinic M 1 , M 3 and M 5 receptors stimulates a cascade of interactions including G protein G␣ q/11 and phospholipase C ␤ activation, resulting in formation of the second messenger inositol triphosphate (IP 3 ) from phospholipids, which subsequently induces release of calcium. The muscarinic M 2 and M 4 receptors are coupled through G␣ i and G␣ o G proteins, and inhibit adenylate cyclase activity and reduce formation of cyclic adenosine 3Ј,5Ј-monophosphate (cAMP). 5 The expression of muscarinic receptor subtypes in the periphery and brain is widespread and heterogeneous. The structural homology of the muscarinic receptor subtypes and poor selectivity of agonists and antagonists has made elucidation of the role of the muscarinic subtypes difficult. However, recent investi-gations using muscarinic receptor knockout mice have helped to elucidate the function of the muscarinic receptors. Muscarinic M 3 receptors are the predominant receptors mediating agonist-induced contractions of smooth muscle, agonist-induced salivation and regulation of pupil diameter. 6 The muscarinic M 2 receptor is highly expressed in the heart, and activation of this receptor by muscarinic agonists induces bradycardia. 7 Thus, the major cholinergic side effects are mediated by muscarinic M 2 and M 3 receptors.
Muscarinic M 1 receptors are highly expressed in forebrain regions such as cortex, hippocampus and striatum, but have low expression levels in the caudal brain regions. 8 The M 1 receptor is predominantly a postsynaptic receptor and mediates pilocarpineinduced convulsant activity and stimulates long-term potentiation, as well as synaptic plasticity. 9, 10 Activation of this receptor is thought to play a key role in cognition. The muscarinic M 2 receptor is expressed throughout the brain and is a major presynaptic autoreceptor. 8 Studies in knockout mice have shown that M 2 receptors mediate temperature regulation, analgesia, corticosterone release and neurotransmitter release. [11] [12] [13] The muscarinic M 3 receptors have a relatively low and homogeneous expression level in brain, but no clear role has been determined. 8 The cAMP-coupled M 4 receptors are thought to be predominately terminal autoreceptors, but also may be localized postsynaptically. Muscarinic M 4 receptors are highly expressed in cortical areas, hippocampus and particularly in the striatum. The muscarinic M 4 receptor knockout mice are hyperactive and hyperresponsive to dopamine D 1 agonists, indicating an important role in movement. 14 Consistent with that finding, muscarinic M 1 /M 4 preferring agonists reduce spontaneous locomotor activity and reverse dopamine agonist-induced behaviors, such as apomorphine-induced climbing in mice. 15, 16 These data also suggest that M 4 receptors may oppose dopamine receptor functions, including mood and motor effects. The expression of muscarinic M 5 receptors has not been shown in the periphery and is highly localized in brain regions, such as the dopamine cell body regions of the substantia nigra and ventral tegmental areas. This distribution has led to the hypothesis that M 5 receptors may control dopamine functions. 17 However, this has not been demonstrated clearly.
Preclinical and clinical studies implicating cholinergic muscarinic agents in regulation of affect
Cholinergic muscarinic mechanisms have been investigated in preclinical models of depression. Muscarinic agonists increase, and antagonists decrease, immobility or 'despair' in the forced swim test model of depression. For example, the cholinesterase inhibitor, physostigmine, but not peripherally acting neostigmine, increased immobility in the forced swim test, suggesting depressogenic activity. 18 The enhanced immobility produced by physostigmine was reversed by the ␤ 1 -adrenergic agonist, metoprolol, indicating the interaction of cholinergic and adrenergic mechanisms in mood. The hypercholinergic Flinders Resistant Line of rats has exaggerated immobility in the forced swim test, as do rats after chronic treatment with muscarinic antagonists to produce cholinergic supersensitivity. 19 Muscarinic agonists without observable parasympathomimetic side effects acutely produce large increases in corticosterone levels in mice, and chronic activation of the hypothalamic-pituitary-adrenal axis is commonly found in depression. Recent studies have shown that muscarinic agonists do not increase corticosterone in the M 2 receptor knockout mice, indicating mediation of the corticosterone response by muscarinic M 2 receptors. 12 As mentioned earlier, stimulation of muscarinic M 4 receptors block dopamine agonist-induced behaviors, including locomotion, suggesting that muscarinic receptors may oppose rewarding and moodelevating activities of dopamine and anhedonia is a primary symptom of depression. 15, 16 These data indicate that overactivation of cholinergic neurons may have depressogenic effects. Based on evidence similar to that cited above, Dilsaver 20 proposed the cholinergicmonoaminergic interaction hypothesis, stating that complex interrelations of cholinergic and monoaminergic neurotransmitter networks may play a role in the pathophysiology and treatment of affective disorders.
In a study in the 1950s, Roundtree et al 21 found that organophosphorous insecticides with cholinesterase inhibition activities produced profound depressionlike states in manic-depressive patients and normal subjects. In contrast, cholinergic antagonists, such as scopolamine, have been reported to produce euphoria, talkativeness and flight of ideas. 22, 23 These and other data led Janowsky et al 24 to propose the 'cholinergicadrenergic hypothesis of mania and depression.' This hypothesis stated hypercholinergic (or hypoadrenergic) drive could produce depression, whereas hypocholinergic or hyperadrenergic drive would cause mania. Furthermore, based on this hypothesis, cholinomimetics would be expected to be antimanic.
In concert with this hypothesis, further evidence supports the role of cholinomimetics in depressed mood in humans. Physostigmine increased depressed mood in manic patients, 25 the non-selective agonist, arecoline, increased depressive-like symptoms in depressed patients 26 and oxotremorine caused depression in patients with Alzheimer's disease. 27 Furthermore, central acting cholinomimetics and direct agonists, but not peripheral acting cholinomimetics, cause decreased rapid eye movement (REM) sleep latency and increased adrenocorticotropic hormone and cortisol levels that mimic changes manifest in depression. [28] [29] [30] The cholinesterase inhibitor, pyridostigmine, increased growth hormone release to a significantly greater extent in depressed patients than in normal subjects, suggesting cholinergic receptor supersensitivity in depressed patients. 31 Miotic responses to eye drops containing the non-selective muscarinic agonist, pilocarpine, were found to be greater in depressed patients than normal subjects, indicating enhanced cholinergic tone in depressed patients. 32 However, more selective cholinomimetics, such as the cholinesterase inhibitor, donepezil, and the muscarinic agonist, xanomeline do not produce prominent depressive-like symptoms. 33, 34 Consistent with antidopaminergic activity of cholinomimetics in animals, physostigmine decreased methylphenidate-induced activation in humans. 35 In support of the hypothesis that mood from depression to mania is a balance influenced by the tone of adrenergic and cholinergic systems, several groups reported that cholinesterase inhibitors lessened manic symptoms in patients. 24, 25, 36 The cholinesterase inhibitor, donepezil, was added to existing therapy in treatment-resistant bipolar patients, and over half of the patients demonstrated marked improvement. 34 Acetylcholine precursors, such as lecithin (phosphotidyl choline) or choline in combination with lithium, have been used to successfully treat manic patients. [37] [38] [39] Interestingly, the muscarinic agonist xanomeline decreased mood swings and psychotic-like behaviors in Alzheimer's patients. 33 Overall, these data in small studies or pilot trials suggest a role for the cholinergic muscarinic receptors in mood, and particularly in treatment, of mania. However, the poor selectivity and tolerability of muscarinic agonists and other cholinomimetics and the low efficacy of agonists for putative target receptors have precluded extensive studies and development of these agents for affective disorders.
Effects of mood stabilizers on cholinergic muscarinic neuronal systems
The effects of mood stabilizers, especially lithium, on neurotransmitters, including cholinergic systems and second messenger systems have been extensively investigated. As found with other neural systems, there are many reported changes produced by lithium in cholinergic systems, but it is not clear if these alterations are direct effects and involved in therapeutic efficacy of lithium, indirect effects or epiphenomenon (for reviews, see Bunney and Garland-Bunney 40 and Dilsaver 41 ). The effects of lithium on muscarinic neurotransmission have been most widely investigated and are not pronounced, but some effects have been noted. Briefly, chronic treatment with lithium increases acetylcholine synthesis and choline uptake. 42 Lithium enhances the expression of muscarinic M 3 receptors and decreases M 2 receptor levels in cultured cells. 43 Overall, accumulating evidence suggests that intracellular signal transduction pathways, rather than membranous neurotransmitter receptors, are targets of mood stabilizers, such as lithium, valproate and carbamazepine. 44 
Proposed mechanism of action of antipsychotic drugs in bipolar disorder
Antipsychotic drugs have been loosely classified into 'typical' and 'atypical' agents. Atypical drugs have Molecular Psychiatry been distinguished due to decreased extrapyramidal symptoms (EPS) and/or efficacy against negative or treatment-resistant symptoms. Typical antipsychotic agents have been widely used in the treatment of mania, particularly in combination with another drug, such as lithium (for review, see Tohen and Zarate 45 ). Although probably not as efficacious as lithium, 46 antipsychotic agents have a more rapid onset and superior initial control of psychomotor activity during acute manic episodes. 47, 48 They are also useful for management of acute psychotic mania, psychotic depression or treatment-refractive bipolar disorder. However, patients with affective disorders may be quite sensitive to induction of EPS and typical antipsychotic agents may precipitate depressive episodes, dysphoria and rapid cycling of mood. [49] [50] [51] Atypical antipsychotics, including clozapine, risperidone and olanzapine have also been used in the treatment of bipolar disorder (for reviews, see Ghaemi and Goodwin 52 and Tohen et al 53 ). They have the major advantage of reduced incidence of EPS. Olanzapine in particular has been clinically investigated in large, double-blind, placebo-controlled clinical trials and has been accepted by the US Food and Drug administration for the treatment of mania. Olanzapine is as efficacious as the mood stabilizer, lithium, in the treatment of mania and is being investigated as a mood stabilizer. 53, 54 Olanzapine has a low rate of reported EPS and does not appear to trigger depressive episodes.
Typical antipsychotic drugs, including haloperidol, are effective in the treatment of mania and there is no clear-cut evidence that one typical antipsychotic is better than another. 45 Haloperidol is selective for dopamine (Table 1) . [55] [56] [57] [58] Therefore, it is likely that dopamine D 2 blockade in limbic areas is a major mechanism of action of typical antipsychotic agents ( Table 2) . Hyperactivity of dopamine neurotransmission in limbic areas has been associated with euphoria, psychosis, emotionality and hyperarousal, symptoms associated with mania. 59 In contrast, excessive blockade of limbic dopamine tracts may produce symptoms of depression, such as anhedonia, anergia, avolition and even precipitation of depression.
The mechanism of action of olanzapine as an antimanic agent, and possibly as a mood stabilizer, is potentially more complex. Olanzapine has a multireceptorial binding profile with interaction at key neurotransmitter systems involved in mood, including high affinity for dopamine D 2 , serotonin 2A , 2C , 6 , ␣ 1 -adrenergic, and histamine H 1 receptor subtypes (Table  1) . 55, 57, 58 This rich interaction with neurotransmitter systems has been described as the multi-acting-receptor targeted-antipsychotic (MARTA) concept. 60 One can hypothesize that olanzapine's blockade of limbic dopamine D 2 receptors 56 may be involved in the antimanic effects of olanzapine (Table 2) . However, the blockade of multiple receptors in limbic and cortical areas may also normalize aberrant neurotransmitter signaling, particularly antagonism of 5-HT 6 receptors which are positively coupled to adenylate cyclase. Thus, antagonism of 5-HT 6 receptors by olanzapine would reduce adenylate cyclase activity. Similarly, the mood stabilizers, lithium, carbamazepine and valproic acid, all decrease neurotransmitter-induced increases in cAMP formation. 61 Furthermore, the downstream effects of alteration of cAMP formation and associated kinases, such as protein kinase C, glycogen synthase kinase 3␤ and myristolated alanine-rich C kinase substrate, may play a key role in the effects of mood stabilizers. 44 However, the direct effect of olanzapine on these kinases has not been investigated.
In regard to depression, olanzapine has multiple activities that may prevent cycling of mood and stabilization of affect. Olanzapine is a potent blocker of serotonin 5-HT 2A receptors, and 5-HT 2A receptor blockade has been proposed to have antidepressant effects. 62 Furthermore, olanzapine-induced increases of extracellular levels of dopamine and norepinephrine in cortical areas presumably stimulate these monoamine systems resulting in elevated mood. 63 The mood stabilizers, valproic acid and carbamazepine, also share the property of increasing prefrontal cortical dopamine levels. 64 The elevation of cortical catecholamines and subsequent increase in neurotransmission may be important, since several cortical areas have been found in imaging studies to be hypoactive in bipolar and depressed patients. 65 Increased catecholamine neurotransmission and subsequent increases in cortical activity are consistent with elevations of Fos expression in prefrontal cortex induced by olanzapine.
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Interaction of antipsychotic drugs with muscarinic receptors
Some of the typical antipsychotic agents, such as thioridazine and chlorpromazine, have relatively high affinity for muscarinic receptors, whereas haloperidol has low affinity, 55, 67 indicating that muscarinic receptor interactions are not required for antimanic activity. The atypical antipsychotics, clozapine and olanzapine, have moderate affinity for muscarinic receptors and risperidone has low affinity (Table 1) . 55, 57, 58, 68 Although activation of muscarinic receptors may have an antimanic action, it is unlikely that any of the antipsychotic agents are efficacious muscarinic agonists. Several publications have indicated that clozapine and olanzapine have agonist activity, particularly at muscarinic M 4 receptors, but these studies were performed in cells transfected with very high density of muscarinic receptors. [69] [70] [71] Cells with density approximating estimates of physiological levels and studies in animal tissue in vitro and in vivo have only shown antagonist activities. 72 For example, olanzapine blocked pilocarpine-induced increases in in vivo phosphoinositide hydrolysis in rats, and alone, did not have agonist activity. 73 Thus, interaction with muscarinic receptors is not likely to play a major role in the mechanism of action of typical and atypical antipsychotics in the treatment of mania.
Hypothesis of antimanic activity of muscarinic M 4 agonists
Although large detailed studies have not been performed on muscarinic agonists and other cholinomimetics in the treatment of mania-probably due to their poor tolerability and pharmacokinetics-there is sufficient evidence to conclude that activation of the cholinergic muscarinic system may produce antimanic activity. We propose that this antimanic activity is mediated by stimulation of muscarinic M 4 receptors (Table 3) . 8, [14] [15] [16] [74] [75] [76] [77] Muscarinic M 4 receptors are found in high density in limbic and cortical structures. 8 Furthermore, they are negatively coupled to adenylate cyclase and, like the mood stabilizers, decrease cAMP formation. 74 Decreases in signal transduction through the cAMP system and subsequent effects on kinases would therefore be expected to have prominent effects on stabilizing potential anomalous neurotransmission in limbic and cortical target regions for mania. Mice with the muscarinic M 4 receptor ablated have been shown to have increased locomotor activity and enhanced response to dopamine agonist-induced behaviors, such as amphetamine-induced locomotion. 14 In contrast, M 4 -preferring muscarinic agonists, such as PTAC, BuTAC and xanomeline, functionally block dopamine agonist-induced behaviors, like apomorphine-induced climbing, without possessing appreciable affinity for dopamine receptors. 15, 16, 75, 76 Xanomeline and PTAC also acutely and chronically block dopamine cell firing selectively in the A10 dopamine pathways that project to the limbic and cortical areas. Xanomeline has recently been shown to increase extracellular dopamine levels and Fos expression in prefrontal cortex, similar to olanzapine, suggesting cortical activation. 77 Thus, M 4 receptors are in high density in the appropriate brain regions purported to be affected in bipolar disorder, and they have the same effects on signal transduction as mood stabilizers. Similar to dopamine antagonists used for the treatment of mania, they functionally antagonize hyperactive dopamine tracts in limbic areas. Finally, 8 Gomeza et al, 14 Bymaster et al, 15 Bymaster et al, 16 Felder et al, 74 Shannon et al, 75 Shannon et al, 76 and Perry et al. 77 Molecular Psychiatry like atypical antipsychotics, they may activate cortical areas by inducing release of dopamine and increasing Fos expression, resulting in downstream effects. Upon development of selective M 4 agonists, clinical trials in mania are warranted for these compounds.
Conclusion
There is a body of evidence suggesting that activation of muscarinic receptors may have an antimanic effect. However, it is likely that mood stabilizers, such as lithium, valproic acid and carbamazepine, do not have effects in bipolar disorder by direct alteration of signal transduction through muscarinic receptors. Furthermore, typical and atypical antipsychotic compounds probably do not have therapeutic activity in mania due to effects on muscarinic receptors. It is proposed that the therapeutic activity of olanzapine in mania is mediated by blockade of dopamine D 2 receptors, as well as antagonism of other neuronal receptors. Moreover, olanzapine may have antidepressant activity and mood stabilization, due to serotonin 2A receptor blockade, increased norepinephrine and dopamine release and cortical activation. Finally, it is hypothesized that muscarinic M 4 agonists have antimanic activity, due to decreased cAMP formation, and functional antagonism of dopamine neurotransmission in limbic areas and cortical activation. It is suggested that there are several seemingly independent mechanistic approaches to the treatment of bipolar disorder. However, further investigation is needed to determine if there is a final convergent pathway to these proposed therapeutic approaches.
